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Abstract
Porcine cytochrome P450 (CYP) 1A2 was purified to electrophoretic homogeneity from the hepatic
microsomes of -naphthoflavone-treated male pigs. In a reconstituted system, this enzyme showed
a good catalytic activity towards caffeine, acetanilide, and methoxyresorufin, all known markers of
mammalian CYP1A2. Using 30- and 50-rapid amplification of coding DNA (cDNA) ends (RACE), we
amplified from the liver RNA of control pigs a full-length 1827 bp cDNA containing an open reading
frame of 1548 bp which encoded a putative CYP1A2 protein of 516 amino acids and an estimated Mr
of 58 380Da. Reverse transcriptase-polymerase chain reaction (RT-PCR) experiments showed that the
messenger RNA (mRNA) of CYP1A2 was expressed in liver, heart and nasal mucosa but not in lung,
small intestine, kidney and brain. Using the pCW vector containing a N-terminal modified cDNA, pig
CYP1A2 was expressed in Escherichia coli. 3-[(3-Chloroamidopropyl)dimethylmmonio]-1-propane-
sulfonate (CHAPS)-solubilized E. coli preparations expressing CYP1A2 produced a functionally
isoform which, in a reconstituted system, was catalytically active toward ethoxyresorufin and
methoxyresorufin showing Km’s similar to those obtained with CYP1A2 purified from pig liver or
human recombinant CYP1A2. Taken together, these results demonstrate that domestic pigs have
a functionally active CYP1A2 gene well expressed in the liver with biochemical properties quite
similar to those corresponding to the human enzyme.
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Introduction
Cytochrome P450 (CYP or P450) comprises a superfamily of enzymes that play a decisive
role in the oxidation of a great number of xenobiotics and endogenous substrates, and
multiple forms of CYPs are present in mammals (Nelson et al. 1996).
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Among various CYPs, CYP1A2 has been of considerable interest because of its role in the
metabolism of drugs (that is, caffeine, theophylline, phenacetin, and warfarin) and activation
of aromatic and heterocyclic amines to reactive metabolites which have carcinogenic potential
(Lewis and Lake 1996; Guengerich 1997). CYP1A2 is primarily a hepatic enzyme and it is
known as one of the major CYP enzymes in the human liver where it represents about
10–13% of the total CYP content (Rendic and Di Carlo 1997). This enzyme is induced in
rodents, and presumably in human, by polycyclic aromatic compounds, cigarette smoke, and
heterocyclic amines formed from the pyrolysis of cooked meats (Buther et al. 1989).
CYP1A2 has been cloned, expressed or purified and characterized in various mammals
including rat, mouse, cat, rabbit, monkey, and human (Guengerich 1997; Sakuma et al.
1997; Tanaka et al. 2006), but not in pig. Indeed, previous studies (Marini et al. 1998;
Skaanild and Friis 1999; Myers et al. 2001) have shown in pig livers the constitutive
expression of a single protein band recognized by antibodies raised against rat CYP1A1 or
recombinant human CYP1A2, probably corresponding to CYP1A2. Thomsen et al. (1991)
also described a partial purification of two CYP proteins of similar molecular weight (about
58 kDa) from -naphthoflavone (NF)-treated pig livers which are probably CYP1A1 and
CYP1A2, but their catalytic activities have not been reported.
Recently, pig has attracted considerably attention as it is believed to be the best animal
species in order to supply an external liver to the construction of bioartificial liver devices for
patients waiting liver transplantation (Chari et al. 1994; Nelson et al. 1996). The use of pig is
also increasing as an animal model to predict the kinetics and toxicity properties of drugs
because of its similarity to human anatomy and physiology (Swindle and Smith 1998).
Various studies have shown that pig liver expresses the main drug-metabolizing enzyme
activities similar to those of human (Anzenbacher et al. 1998; Donato et al. 1999; Soucek
et al. 2001). However, detailed investigations on the enzymology of porcine CYP enzymes,
necessary to extrapolate to humans the results found in pigs, are limited to a few isoforms
(Lundell 2002; Lin et al. 2004; Sakuma et al. 2004; Baranova et al. 2005; Skaanild 2006).
Therefore, it appeared important to study porcine CYP1A2 in detail to extend one’s
understanding of the drug-metabolizing capacity of the pig as a possible animal model in
replacement of dog or monkey, species widely used in pharmacology and toxicology.
In the present study we report the purification of this enzyme from livers of NF-treated
male domestic pigs, the molecular cloning of cDNA encoding this porcine enzyme, its
expression in Escherichia coli, and a detailed study of its enzymatic properties.
Materials and methods
Chemicals
Caffeine, 1,7-dimethylxanthine, beta-naphthoflavone, acetanilide, 2-aminofluorene,
n-octylamine, 4-hydroxy-acetanilide, methoxyresorufin, resorufin, ethoxyresorufin, sodium
cholate, 3-[(3-cholamidopropyl)-dimethylamonio]-1-propanesulfonate (CHAPS), and
3-morpholinopropanesulfonic acid (MOPS) were supplied from Sigma Chemical Co. (St
Louis, MO, USA). Sepharose 4B and DEAE Sephacel were purchased from Pharmacia
(Uppsala, Sweden), whereas DEAE cellulose (DE53) and carboxymethyl cellulose 52 (CM)
were from Whatman (Clifton, USA) and hydroxyapatite (HA) was from Clarkson Co.
(Williamsport, USA). Emulgen 911 was from CAO Corp. (Tokyo, Japan). Mouse
monoclonal antibodies against recombinant human CYP1A2 were purchased from
Panvera (Madison, WI, USA), whereas polycloned antibodies against rat CYP1A1 were
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from Gentest (Woburn, MA, USA). All chemicals and reagents were of analytical grade.
Tripure Isolation reagent and restriction enzymes were from Roche Molecular Biochemicals
(Indianapolis, USA). ThermoScript III RT, Gene Racer Kit, Platinum Pfx Taq Polymerase
were from Invitrogen Life Technologies (Carlsbad, CA, USA). Master Mix PCR, pGEM-T
easy vector, Wizard Plus SV MiniPrepsDNA Purification System were purchased from
Promega (Madison, MI, USA). Peroxidase-conjugated anti-mouse immunoglobulin G
(IgG) and oligonucleotides were obtained from Sigma-Aldrich (Milan, Italy). PCW Ori plus
plasmid containing human CYP1A2 was kindly supplied by Professor F. P. Guengerich
(Nashville, TN, USA). -Nicotinamide adenine dinucleotide phosphate (NADPH)-
cytochrome P450 reductase was purified from rats as previously reported (Amato et al.
1996).
Animal treatment and preparation of microsomes
This study was performed using male castrated Largewhite per Landrace hybrid domestic
pigs (30–35 kg body weight) of about 3 months old. The animals, supplied by a commercial
farm, were housed in floored indoor pens, received food and drinking water ad libitum, and
were maintained on a 12-h light/dark cycle. After a preliminary period of 15–20 days to allow
adjustment of the pigs to diet, temperature and humidity conditions, two pigs were given
an intraperitoneal suspension of -naphthoflavone (NF) in corn oil (30mg kg1) for
4 days and were sacrificed 24 h after the final injection. Eight control pigs were given
an intraperitoneal injection of the vehicle (corn oil) alone. Throughout the study all animals
were under clinical observation. Liver microsomes were prepared as previously published
(Longo et al. 1991) from two control and two NF-treated animals. Microsomal protein
concentration was measured by the method of Lowry et al. (1951) using bovine serum
albumin as the standard. Surgical procedures and experimental protocols were approved
by the Animal Care Committee of Bologna University.
Isolation of total RNA and cDNA synthesis
Total RNA was extracted from control pigs liver, lung, small intestine, heart, kidney, brain
and nasal mucosa (80–100mg of tissue) with TriPure Isolation Reagent, as recommended
by the manufacturer. The resulting pellet was resuspended into 25–50 ml sterile DEPC
water, as required. RNA (1 mg) was reverse transcribed, after DNAse treatment, with 1U
of ThermoScript RT in the presence of random hexanucleotide primers according to the
manufacturer’s instructions.
PCR and sequence analysis
The primers used to identify CYP1A2 and glyceraldehyde 6-phosphate dehydrogenase
(GAPDH) were constructed by the OLIGO 4.0 program on the basis of conserved regions
of homologous murine, rat and human genes retrieved from GeneBank; the CLUSTAL X
program was used for multiple sequence alignment. A total of 2 ml of cDNA were added to
a PCR Master Mix for the amplification reaction (35 cycles). The DNA fragments were
separated on 1% agarose gel and subsequently stained with ethidium bromide. Polymerase
chain reaction (PCR) products were purified by a Wizard SV Gel and PCR Clean-Up
system, as indicated by the manufacturer, and were sequenced by automated fluorescent
cycle sequencing by BMR Genomics Sequencing Core Service (University of Padua).
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The sequence homology between pig and human genes was calculated by using the BLAST
program.
CYP1A2 cDNA cloning and sequencing
Total RNA was prepared from liver of untreated pig with Tripure Isolation reagent
and modified by a Gene Racer Kit and reverse transcribed with 1 U of ThermoScript III RT
according to the manufacturer’s instructions. Firstly, a CYP1A2 cDNA central fragment of
520 bp was cloned with two primers obtained by a multi-alignment strategy from the
sequences encoding CYP1A2 isoforms of other species (forward primer 50-GCCTGACCT
CTACACCTC-30 and reverse primer 50-GTGATGTCCCGGACACTGTTC-30). The
PCR programme consisted of 35 cycles (20 s at 94C, 30 s at 52C and 1min at 72C) with
Master Mix PCR. The full-length cDNA was obtained employing for the isolation of the
missing 50-end, the following two reverse primers: 50-TCCCGATAGCGCTCCTGG
ACCATT-30 (racer primer) and 50-TGGGCAGATATCTAAGGATGGGG-30 (nested
primer); and for the isolation of the missing 30-end, the following two forward primers:
50-AACACCTTCTCCATTGCCTCAGACC-30 (racer primer) and 50-TGATGGCAGGG
CCTGGGCACTTT-30 (nested primer). These primers were chosen from the central
fragment sequence firstly isolated using proof-reading Platinum Pfx Taq Polymerase
according to the Invitrogen Gene Racer Kit. The PCR products were gel purified and
cloned into pGEM-T easy vector and sequenced. The homologies were performed with the
NCBI-BLAST database.
Construction of expression plasmid for pig CYP1A2
For the expression of pig CYP1A2 cDNA, the nucleotide sequence encoding its wild-type
N-terminal region was changed to include the MALLLV amino acids sequence and
the NdeI site, as previously reported (Fisher et al. 1992), using the sense primer
50-GCCCATATGGCTCGTTTATTAGCAGTTTTTTTCTCAGCCACAGAG-30 and
the antisense primer 50-CTGGTAACTTCATTTGATGG-30, containing the STOP
codon. The PCR product was subcloned in pGEMT-easy vector for sequencing and to
confirm the modified sequence. Finally, recombinant CYP1A2 cDNA was digested using
NdeI site and SalI restriction site present in pGEMT-easy vector and ligated in the
pCWOriþ vector.
Expression of pig CYP1A2 and human CYP1A2 pCWoriþ plasmids
Plasmids were transformed in Escherichia coli DH5 cells. A single resistant colony of
DH5cells transformed with each plasmid was grown overnight a 37C in Luria–Bertani
(LB) medium containing 100 mgml1 of ampicillin. A 10ml aliquot of LB pre-culture was
inoculated into 1 litre of terrific broth (TB). The TB medium was supplemented with
ampicillin (100 mgml1), 1mM thiamine, 0.5mM -aminolevulenic acid and trace elements.
The culture was incubated at 30C in a bath with vigorous shaking; after 2.5 h isopropyl
-D-thiogalactopyranoside (1mM) was added to induce the tac promoter and culture was
maintained 24 h for the expression of pig CYP1A2 or 48 h for the expression of human
CYP1A2.
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CHAPS-solubilization of Escherichia coli-expressing pig and human CYP1A2
E. coli membranes containing pig or human CYP1A2 were solubilized as previously
described (John et al. 1994). The culture cells were pelleted at 5000 rpm for 15min at 4C.
The pellet was resuspended in 40ml of MOPS buffer (100mM MOPS pH 7.3, 10%
glycerol, 0.2mM dithiothreitol (DTT), 1mM ethylenediamine tetra-acetic acid (EDTA))
and centrifuged as above. The pellet was again resuspended in MOPS buffer and sonicated
several times with cycles of 15 s on and 5 s off. The sonicated sample was ultracentrifuged at
33 000 rpm for 30min at 4C. The pellet was suspended in 10ml of MOPS buffer and
stirred for 2 h at 4C after the addition of CHAPS (0.5%). Finally, the sample was
ultracentrifuged for 30min at 4C and the supernatant, containing the CHAPS-solubilized
CYP1A2 preparation was stored at –80C until use.
RT-PCR for tissue distribution studies
Total RNA (1 mg), extracted from the seven above-mentioned tissues of control pigs, after
retrotranscription, was used for reverse transcriptase-polymerase chain reaction (RT-PCR)
with a programme and primers for the 520 bp fragment previously described. The PCR
products were analysed on agarose gel, purified and sequenced.
Immunoblot analysis
Microsomal proteins from liver (generally 10 mg) were separated according to Laemmli
(1970) on sodium dodecylsulphate (SDS) 7.5% or 10% (w/v) polyacrylamide gel and then
transferred electrophoretically onto nitrocellulose membranes following the method of
Towbin et al. (1979). Immunodetection of CYP was performed either with anti-rat CYP1A1
(dilution 1 : 1000) or with anti-recombinant human CYP1A2 (dilution 1 : 2000) as the
primary antibodies; the bands were visualized with a peroxidase-conjugated anti-rabbit
IgG or anti-mouse IgG (dilution 1 : 1500). In all cases, in our experimental condition
both antibodies recognized a single protein band in microsomes from either control or
NF-treated pigs. The intensity of protein bands was quantified by densitometry.
Purification of CYP1A2
The purification of porcine CYP1A2 was carried out in a sequence of steps (all performed at
4C) similar to those previously described (Puccini et al. 1992). Microsomes obtained from
a NF-treated pig were resuspended in 0.1M potassium phosphate buffer (pH 7.2)
containing 1mM EDTA, 1mM DTT, 0.1mM phenylmethanesulphonyl fluoride (PMSF)
and 20% glycerol (solubilization buffer). They were solubilized with the addition of 0.6%
sodium cholate for 30min. The mixture was then centrifuged at 100 000 g and the
supernatant was applied onto a n-octylamine-Sepharose 4B column (2.5 50 cm). After
washing, the column was eluted with the same solubilization buffer containing 0.5% cholate
and 0.05% emulgen. This fraction (fraction I) contained most of the CYP (1158 nmol) but
not CYP1A1/2 as monitored by Western blot analysis with anti-rat CYP1A1. Fraction II,
which contained CYP1A1/2, was eluted from the 4B column with the above solubilization
buffer containing 0.5% cholate and 0.2% emulgen. This fraction II was concentrated by
ultrafiltration (Amicon PM-30 membrane), extensively dialysed against 10mM potassium
phosphate pH 7.2, 1mM EDTA, 20% glycerol, brought to 0.6% emulgen and loaded onto
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a DEAE Sephacel anion-exchange column (1.6 35 cm) pre-equilibrated with this buffer.
Most of the CYP (256 nmol) was recovered in the flow-through (DE-Sephacel fraction I)
but it did not contain CYP1A1/2 and was left aside. The fraction enriched of CYP1A2
(DE-Sephacel fraction II) was eluted with the above buffer containing 50mM NaCl, while
a fraction containing CYP1A1 among other proteins was eluted with the same buffer
containing 300mM NaCl, and left. This chromatographic separation of CYP1A2 from
CYP1A1 with DEAE-column by salt gradient was previously described in the separation of
the corresponding isoforms from liver of treated rats (Ryan et al. 1980).
The DE-Sephacel fraction II after concentration and dialysis against 5mM potassium
phosphate pH 7.8, 1mM EDTA, 20% glycerol, was loaded on a DE 53 column
(1.6 15 cm), pre-equilibrated with this buffer and 0.6% emulgen. The fraction enriched of
CYP1A2 was eluted with the same buffer containing 30mM NaCl. This fraction was
concentrated and dialysed against 10mM potassium phosphate pH 6.8, 1mM EDTA, 20%
glycerol and loaded into a CM column (1.6 20 cm) pre-equilibrated with the same buffer
and 0.5% emulgen. A fraction containing CYP1A2 as a single protein band, as judged by
electrophoresis and Western blot, was eluted from this column by the above buffer plus
100mM NaCl. The eluate from the CM was concentrated, dialysed against 10mM
potassium/phosphate pH 7.2, 1mM EDTA, 20% glycerol and loaded into a small
hydroxyapatite (HA) column (1.6 5 cm). After an extensive washing with the above buffer,
containing 0.3% cholate to replace emulgen, the CYP1A2 was eluted with 0.25M potassium
phosphate pH 7.2 plus 0.3% cholate, concentrated and dialysed extensively (48–72 h) to
remove cholate against 100mM potassium phosphate pH 7.2, 1mM EDTA, 20% glycerol
and then stored at –80C. Table I shows the results of a CYP1A2 purification procedure.
Similar results were obtained when CYP1A2 was purified from liver microsomes of another
NF-treated pig. The identity and molecular mass of this protein was also determined by
time-of-flight mass spectrometry (Protein Analysis Facility, Lausanne University, Lausanne,
Switzerland), where an Mr of 58 kDa was obtained confirming that the purified protein was
the porcine CYP1A2 devoid of a significant CYP1A1 contamination.
Enzyme assays
Cytochrome P450 content was measured by the method of Omura and Sato (1964).
Ethoxyresorufin O-deethylase (EROD) and methoxyresorufin O-demethylase (MEROD)
activities were determined by measuring the production of resorufin, as previously reported
(Lubet et al. 1985), with a Perkin-Elmer spectrofluorimeter (model LS 45). The rates of
aniline hydroxylation (AnH) and of 6 -testosterone hydroxylase (6 T-H) were measured
as previously described (Longo et al. 1991). Acetanilide hydroxylase (AcH) was determined
Table I. Purification of CYP1A2 from liver microsomes of a NF-treated pig
Fraction Total CYP (nmol)
Specific CYP content
(nmol/mg prot.) Yield
Solubilized microsomes 2865 0.68 100
Sepharose 4B column fraction II eluate 560 1.7 19
DE Sephacel fraction II eluate 92 3.3 3
DE 53 fraction I eluate 38 5.6 1.3
CM 0.1MNaCl eluate 15 8.7 0.5
HA 0.25 M K/phosphate eluate 8.4 11.2 0.3
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by high-performance liquid chromatography (HPLC) as described by Tsyrlov et al. (1993).
Caffeine oxidation was focused on the 3-demethylase (Caf-3D) activity using an HPLC
method proposed by Agundez at al. (1992). 2-Aminofluorene hydroxylase (2-AmFH)
activity was determined according to Vanderslice et al. (1987). The activities of the purified
enzyme were determined, as described previously (Puccini et al. 1992), in a reconstituted
system containing in about 0.3ml, 0.1 nmol of CYP1A2, 0.3 nmol of rat NADPH-
cytochrome P450 reductase, 30 mg of fresh sonicated dilaurylphosphatidylcholine which had
been pre-incubated for 30min at room temperature. Then, after the addition of phosphate
buffer pH 7.4, the substrate and NADPH (1mM) were added to a final volume of 1ml, and
the complete system was incubated for 20min at 37C. Under these conditions the catalytic
activities were found to be optimal for all the tested substrates.
Kinetic parameters (Km and Vmax) for the EROD and MEROD fluorescent assays were
investigated in a reconstituted system containing the 50 pmol of purified CYP1A2 or
CHAPS-solubilized E. coli preparations of porcine CYP1A2 or human CYP1A2 (50 pmol),
100 pmol of rat NADPH-cytochrome P450 reductase and 30mg of fresh sonicated
dilaurylphosphatidylcholine. The reactions were performed as described before. Kinetic
parameters were determined using non-linear regression analysis with GraphPad Prism
software.
Inhibition experiments were performed to evaluate the sensitivity of pig and human
recombinant CYP1A2. The inhibitory effects on EROD activity of -naphthoflavone or
ellipticine, two known inhibitors of human CYP1A2 (Tassaneeyakul et al. 1993), were
examined. The assay method was carried out in a reconstituted system as previously
described using a fixed substrate concentration (3 mM) and varying inhibitor concentrations.
IC50 were estimated by interpolation.
Results
Purification of CYP1A2
In order to study the catalytic properties of porcine CYP1A2, we have purified this enzyme
from the NF-treated pigs by methods previously described (Ryan and Levin 1990; Puccini
et al. 1992). The purification was performed from induced pigs, as the CYP1A2 content
could be too low in the young control ones.
As reported earlier (Thomsen et al. 1991), the treatment of pig with NF doubled the
hepatic microsomal CYP content (from 0.31 to 0.62 nmolmg1 protein in the control and
treated animal, respectively).
As seen in Figure 1 and Table I, CYP1A2 has now been purified from microsomes to
apparent homogeneity by various chromatographic steps. The specific content of the
purified enzyme, which had an apparent Mr of about 57 kDa, was 11.2 nmol of CYPmg1
protein, a value lower than that theoretically expected (about 16 nmolmg1 protein)
suggesting a significant presence of CYP (heme-free) apoprotein.
Spectral property of purified CYP1A2
The maximum absorbance of the reduced carbon monoxide complex of the purified
CYP1A2 was at 448 nm, as previously reported by Thomsen et al. (1991). The absolute
spectrum (Figure 2) of CYP1A2 had a Soret maximum at 393 nm, indicative of a pre-
dominant high-spin state as observed for other mammalian CYP1A2 (Guengerich 1997).
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Figure 2. Absolute spectra of purified cytochrome P450 (CYP) 1A2 (3.4 mM) in 100mM potassium
phosphate buffer, pH 7.2, 20% glycerol, 0.1mM ethylenediamine tetra-acetic acid (EDTA).
Figure 1. Gel electrophoresis of microsomal proteins at various stages of cytochrome P450 (CYP) 1A2
purification. Lane 1 contained solubilized microsomes from NF-treated pig; lane 2, fraction II eluted
from the DE Sephacel column; lane 3, fraction I eluted from the DE 53 column; lane 4, fraction eluted
from the CM column; and lane 5, fraction eluted from the HA column.
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Drug oxidation activities
The oxidation activity of CYP1A2 towards a number of typical substrates for mammalian
CYP1A2 (Lewis and Lake 1996) was compared, in a reconstituted monooxygenase system,
with that of hepatic microsomes from NF-treated pigs.
As shown in Table II, purified CYP1A2 is active on the oxidation of caffeine, acetanilide,
methoxyresorufin, ethoxyresorufin and 2-aminofluorene. On the other hand, the oxidation
of aniline or testosterone was not catalysed by porcine CYP1A2. The porcine enzyme
catalysed more specifically the oxidation of caffeine, acetanilide and methoxyresorufin: their
rates were about four- to six-fold higher in the reconstituted system than in the NF-treated
microsomes.
Immunodetection analysis
To evaluate the constitutive expression of CYP1A2, we determined two marker activities
(MEROD and AcH) and performed immunoblotting on hepatic microsomes prepared from
eight control pigs. The monoclonal antibodies raised against human CYP1A2 detected in
the liver microsomes of all pigs a single band (Figure 3) whose interindividual variation
correlated positively with the activities of MEROD (r¼ 0.92) and of AcH (r¼ 0.58) but not
with those of EROD (r¼ 0.27). The hepatic protein band recognized by these antibodies
should only account for the expression of CYP1A2 as these antibodies do not cross-react
Table II. Catalyitc activities of CYP 1A2 and hepatic microsomes from a NF-treated pig.
Activity (nmol/min/nmol CYP)
Substrate Microsomes CYP 1A2
Caf-3D 0.124 0.750
AcH 0.856 5.88
MEROD 0.043 0.174
EROD 0.776 0.575
AnH 0.211 N.D.
2-AmF-H 0.366* 0.353*
6T-H 0.437 N.D.
The catalytic activities were measured as described in the Materials and Methods. Caf-3D,
caffeine 3-demethylase, AcH, acetanilide hydroxylase, MEROD, methoxyresorufin
O-demethylase; EROD, ethoxyresorufin O-deethylase; AnH, aniline hydoxylase; 2-AmFH,
2-aminofluorene hydroxylase; 6T-H, 6-testosterone hydroxylase, The data are the mean of
duplicate experiments. *This activity is expressed as fluorescence/min/nmol CYP.
N.D.¼not detectable.
Figure 3. Western blotting of cytochrome P450 (CYP) 1A2 in hepatic microsomes from eight control
pigs (lanes 1–8) using monoclonal antibodies anti-human CYP1A2. Lanes 9 and 10 contained, as
a reference, 0.1 and 0.5 pmol of purified pig CYP1A2, respectively.
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with human CYP1A1. However, both the immunoblots and marker activities revealed
an interindividual variation in the expression of CYP1A2 in porcine liver. Quantitative
Western blots, using purified CYP1A2 concentrations as the standard curve, showed that
CYP1A2 varied from approximately 3% to 9% of the total CYP present in pig liver
microsomes.
Cloning and nucleotide sequencing of porcine CYP1A2
Oligonucleotide primers for RT-PCR were designed on the base of the conserved regions of
the mammalian CYP1A2 isoforms retrieved from GeneBank. A 520 bp PCR product was
obtained and, after sequencing, it resulted in being highly homologous to human CYP1A2.
Nucleotides in the 50- and 30-regions of the cDNA were obtained by using the 5- and
3-RACE procedures. The sequence of the full-length cDNA, which was 1827 bp (Figure 4),
contained a 69-nucleotide 50-UTR, an open reading frame of 1548 bp and a 210 bp 30-UTR.
The cDNA encoded a protein of 516 amino acids with an estimated molecular weight of
58 380 Da. This sequence was subsequently submitted to GeneBank and then compared
with those of other animals.
CYP1A2 of pig had a high degree of nucleotide and amino acid sequence identity with the
reported sequences for the CYP1A2 of other mammals (Table III), but, as expected, shared
a lower amino acid identity (76%) with the pig CYP1A1 (GeneBank accession number NM
24412). The porcine CYP1A2 gene appeared to be more similar to the corresponding genes
of Bos taurus (accession number XM 59450) Balaenoptera acutorostrata (accession number
AB 231892), Homo sapiens (accession number NM 012541), and Macaca fascicularis
(accession number D 86474) than those of Canis familiaris (accession number NM
001008720) or Rattus norvegicus (accession number NM 012541). The N-terminal
sequence of CYP1A2 contained approximately 20 hydrophobic amino acids preceding by
a halt-transfer signal containing positively charged amino acids and a proline rich region
(residues 42–54), necessary for proper protein folding (Kemper 2004). CYP1A2 possessed
a putative heme-binding domain (residues 451–460) around Cys458 that was well conserved
among the mammalian CYP1A2 proteins (Figure 4). The sequences alignment of the
putative substrate recognition sites of pig CYP1A2 and those of mammalian orthologues
showed a degree of highly conserved amino acids which ranked in the following
order: Macaca fascicularis>Bos taurus>Homo sapiens>Canis familiaris>Balaenoptera
acutorostrataRattus norvegicus (Table IV). The terminal nucleotide sequence of 30-UTR,
although incomplete, showed no identity with those of human or rat CYP1A2s.
Table III. Nucleotide and amino acid sequence identity between CYP1A2 of pig and the CYP1A2 of
other mammals.
Nucleic acid
Amino acid
Species % identity % Identity % Similarity
Bos taurus 87 82 91
Balaenoptera acutorostrata 88 82 90
Homo sapiens 85 81 90
Macaca fascicularis 85 81 89
Canis familiaris 83 77 87
Rattus norvegicus 78 73 85
1462 A. Messina et al.
Figure 4. Nucleotide and deduced amino acid sequence of the pig cytochrome P450 (CYP)1A2. The
putative initial ATG start codon, the TGA stop codon and the observed mutant nucleotides are
emboldened; the haem region is boxed, and the six putative SRS regions are underlined.
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Mutation analysis of porcine CYP1A2
In order to identify any prominent genetic polymorphism of CYP1A2 in pigs, PCR analysis
was performed in the liver of eight animals. Sequences analysis detected a polymorphism in
five coding regions: at protein position 198 (gca! gcg), 211 (cgc! tgc), 231 (caa! ccg),
328 (aac! gac) and 402 (gct! gcc).
These mutations, except those in positions 211 and 328, are silent mutations since they
do not result in a different amino acid sequence. In contrast, a mutation at position 211
(detected in four animals out of eight) caused an amino acid change from R to C,
and, likewise, a mutation at position 328 (detected in two animals out of eight) caused
a replacement D with N, an amino acid known to be present in other mammalian CYP1A2.
Porcine and human CYP1A2 enzymes expressed in Escherichia coli.
The porcine and human CYP1A2 were expressed separately in E. coli DH5 cells. Both
CHAPS-solubilized pig and human CYP1A2 preparations from E. coli showed the reduced
carbon monoxide difference spectra with a predominant absorption peak at 448 nm and
a little peak at 420 nm (spectra not shown). These results indicated that both pig and human
CYP1A2 were expressed as the holo-enzymes. Based on these difference spectra, the
Figure 5. 7-Ethoxyresorufin O-deethylase (EROD) assay (3 mM substrate concentration) was
performed with pig (g) or human (m) recombinant cytochrome P450 (CYP) 1A2 in a reconstituted
system and inhibitor concentrations of -naphthoflavone (A) and ellipticine (B). Values, expressed as
percentages of control activity, are the mean of two experiments which differ by less than 8%.
Table IV. Sequence comparison between swine CYP1A2 and other mammalian orthologues at substrates
recognition sites (SRS 1-6) and heme binding domain
Domain
Sus scrofa
aa residues
in CYP1A2
Homo
sapiens
CYP1A2
Macaca
fascicularis
CYP1A2
Balaenoptera
acutorostrata
CYP1A2
Bos taurus
CYP1A2
Canis
familiaris
CYP1A2
Rattus
norvegicus
CYP1A2
SRS1 107-130 75 83 95 100 87 87
SRS 2 218-228 80 93 55 55 33 55
SRS 3 252-260 80 80 40 93 93 55
SRS 4 305-321 87 87 93 81 93 75
SRS 5 379-390 87 93 93 100 100 100
SRS 6 491-500 100 100 93 93 100 100
HEME 451-460 100 90 100 100 100 90
Percentage of identity with the pig sequence.
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CHAPS-solubilized preparations yielded about 17.4 nmol of pig CYP1A2 and 13.6 nmol of
human CYP1A2 per litre of culture, respectively.
EROD and MEROD kinetic assays
EROD and MEROD assays were performed using microsomes from control pigs, CYP1A2
purified from liver, solubilized E. coli membrane preparations containing pig CYP1A2 and
were compared with E. coli preparations containing human CYP1A2 (Table V). The
apparent Km values for both reactions either relative to pig CYP1A2 or to human
counterpart showed a high degree of similarity. Furthermore, in all systems the pig CYP1A2
showed a lower Km for EROD compared with that for MEROD, as previously reported for
the human orthologous (Kim et al. 2008). On the other hand, the apparent Vmax values
showed differences among the various enzymatic reactions. As expected, the apparent Vmax’s
for both EROD and MEROD of pig recombinant CYP1A2 were higher than those obtained
with pig liver microsomes but lower than those of CYP1A2 purified from pig liver.
It is of interest to note that the apparent Vmax value of recombinant pig CYP1A2 for
MEROD, unlike EROD, was higher than that of recombinant human CYP1A2 suggesting
that this activity may be a better marker for this enzyme in pig than in human.
Chemical inhibition assays
Inhibition properties of pig and human CYP1A2 by -naphthoflavone and ellipticine were
determined using CHAPS-solubilized recombinant enzymes in a reconstituted system. The
effects of -naphthoflavone and ellipticine on EROD activity catalysed by pig and human
CYP1A2 were examined (Figure 5). In both cases, the best inhibitor was ellipticine. The
IC50 value for -naphthoflavone was eight times lower for recombinant human CYP1A2
(55 nM) compared with pig counterpart (450 nM). Conversely, the IC50 value for ellipticine
was five-fold lower for pig CYP1A2 (2.5 nM) compared with human counterpart (9.2 nM).
Tissue distribution of CYP1A2
The tissue distribution of CYP1A2 mRNA in the pig was analysed by RT-PCR using
specific primers. As shown in Figure 6, an intense band corresponding to the size of the
Table V. Kinetic parameters of EROD and MEROD activities with recombinant pig and human CYP1A2, hepatic
microsomes from control pig and CYP1A2 purified from NF-treated pig.
EROD MEROD
Parameters Km (mM) Vmax* Km (mM) Vmax*
Recombinant pig 1A2 0.41 0.035 3.1 0.013
Recombinant human 1A2 0.85 0.090 2.6 0.007
Pig liver microsomes 0.64 0.008 2.2 0.001
1A2 purified from pig liver 0.34 0.712 1.8 0.218
The incubations were performed as reported in the Material and Methods. Substrate concentrations ranged
from 0.1 to 10 mM. Values are the mean of two experiments that differ less than 23%. *values expressed as
nmol/min/nmol P450.
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expected amplified region (520 bp) was obtained using the total RNA from liver. A weak
band of the same size was also observed with the total RNA from heart and nasal mucosa,
whereas no bands were seen with the total RNA from lung, small intestine, kidney and brain.
Specific primers for GAPDH were used as a control for RT-PCR experiments.
Discussion
In previous works, the cytochrome P450 (CYP) 1A2 gene and enzyme have been
characterized in a number of mammalian species, but similar studies have so far been
missing in pigs (Guengerich 1997; Sakuma et al. 1997; Tanaka et al. 2006). We have now
isolated the CYP1A2 enzyme from -naphthoflavone (NF)-treated pigs, characterized
some of its biochemical properties and cloned the coding DNA (cDNA) encoding this
enzyme. Using methods similar to those employed in the isolation of other mammalian
CYPs (Ryan and Levin 1990; Marini et al. 1998), we have purified to apparent homogeneity
the porcine CYP1A2, which, as previously reported (Thomsen et al. 1991), was obtained
predominantly in the high-spin state. As expected, the purified protein had catalytic
properties common to those of other CYP1A2 enzymes; it was found to be catalytically very
active towards the typical substrates of CYP1A2 enzymes such as caffeine, acetanilide,
methoxyresorufin, ethoxyresorufin and 2-aminofluorene. In particular, the catalytic
activities of the purified protein towards caffeine, methoxyresorufin and acetanilide, all
known marker substrates for CYP1A2 enzymes (Lewis and Lake 1996), were markedly
increased over those found with liver microsomes from NF-treated pigs. Interestingly, the
purified pig enzyme, unlike rat CYP1A2 (Ryan and Levin 1990), failed to oxidize aniline or
testosterone (in the 6 -position), a property shared with human CYP1A2 (Waxman et al.
1991; Ono et al. 1996), thereby indicating a closer substrate specificity between pig and
human enzymes than between rat and human counterparts.
We have also studied the expression of CYP1A2 in the hepatic microsomes of control
pigs, and found a positive correlation between the results of immunoblot analysis and those
of selective CYP1A2 activities (methoxyresorufin O-demethylase (MEROD) and acetanilide
hydroxylase (AcH)) suggesting that this isoform is expressed constitutively in pig liver and
that the antibodies employed can only recognize this enzyme. More work is, however,
necessary to exclude conclusively that these antibodies can also recognize, in addition to
CYP1A2, any constitutively expressed CYP1A1, which has an Mr similar to that of CYP1A2
(Thomsen et al. 1991). In human liver, CYP1A2 accounts for about 10–13% of the total
Figure 6. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of cytochrome P450
(CYP) 1A2 messenger RNA (mRNA) in various organs of control pigs: liver (Li), heart (H), nasal
mucosa (NM), lung (Lu), intestine (I), brain (B), and kidney (K). Polymerase chain reaction (PCR)
products were separated by electrophoresis on agarose gel and stained with ethidium bromide.
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CYP content (Rendic and Di Carlo 1997) and is essentially the only constitutively expressed
enzyme of CYP1A subfamily. Assuming that this also applies to the livers of our young male
domestic pigs, the constitutively expressed CYP1A2 isoform was found to be 3–9% of the
total CYP content and showed a significant interindividual variation.
In order to characterize further this porcine enzyme, we isolated and cloned the cDNA of
CYP1A2 by using a polymerase chain reaction (PCR) approach followed by 30- and 50-rapid
amplification of cDNA ends (RACE). The CYP1A2 cDNA isolated in this study was
1827 bp long and contained an open reading frame of 1548 bp encoding a protein of 516
amino acids and the 50- and 30-non-coding regions. The number of amino acids of the
porcine protein is the same as that reported for human CYP1A2 and that of the common
minke whale, and several monkey species (Niimi et al. 2005; Narimatsu et al. 2005) but
different to that reported for dog, cat and rodents (Uchida et al. 1990; Lewis and Lake 1996;
Tanaka et al. 2006). When compared with other CYP1A2 enzymes across species, the
porcine gene and its substrate recognition sites (Gotoh 1992) shared a higher identity with
the sequences of monkey, human and bovine CYP1A2 than with those of dog or rodents.
The degree of identity between pig and human CYP1A2 varies according to the substrate
recognition sites (SRS) considered, going from a maximum of 100% for SRS6 to
a minimum of 75% for SRS1, a region latterly involved in the flexible channel of substrate
entry into the active site cavity. The comparison between the overall amino acid composition
of porcine CYP1A2 with that of human CYP1A2 demonstrated that most differences
represented conservative changes, i.e. involved replacement of amino acid residues with
others possessing similar chemical properties.
A more detailed comparison of the amino acid sequence of pig CYP1A2 with that of
human protein, which takes into account the recently resolved human structure (Sansen
et al. 2007), revealed specific motives of interest.
Among the amino acid residues F226, Thr223, Asp320, Tyr189, Val220, Thr498 and
Lys500, which participate in an extensive network of hydrogen-bonded water and side-
chains in the active site of human CYP1A2, only Thr223 was not shared by the porcine
counterpart where Ser223 was found.
The amino acids Thr118, Ser122 and Thr124 that characterize the B0-region (SRS1) of
the human CYP1A2 structure were all shared by the porcine enzyme. A significant
difference was found in amino acid 322, which was Val in pig and Leu in human. This
variation is thought to be important for modifying the catalytic preference of CYP1A2 and
CYP1A1 with respect to MEROD and 7-ethoxyresorufin O-deethylase (EROD),
respectively (Liu et al. 2004).
Due to the use of domestic hybrid pigs, various single nucleotide polymorphisms (SNPs)
(n¼ 5) were found in the sequence analysis of the CYP1A2 gene, even though a small
number of animals (n¼ 8) were used. However, of the five differences of nucleotides
observed, only two resulted in a change of amino acid (R 71C and D 110N). In this regard,
it is of interest to note that amino acid R 71 is shared with human and marmoset but not with
cynomolgus and Japanese monkeys or other mammals (Lewis and Lake 1996; Narimatsu
et al. 2005). Of course, the influence of these different amino acids on the activity of
CYP1A2 remains to be examined. However, in the present study, which was limited to only
a few pigs, no important mutations including non-sense mutations have been brought to
light, as reported in dogs (Mise et al. 2004).
To express pig CYP1A2 in Escherichia coli, a construct was prepared with the modification
of seven codons in the 50 terminal of CYP1A2 cDNA as reported by Fisher et al. (1992) and
examined for the expression in the pCW vector. The present results support the well-
demonstrated utility of this N-terminal modification on the expression of CYP in E. coli.
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Indeed, the expression of porcine CYP1A2 was completely dependent upon modification of
the N-terminal. With the optimization with respect to the induction time (24 h) and
temperature (30C), 15–18 nmol of CYP1A2 l1 of culture were routinely recovered in the
E. coli membranes, a yield similar to that found for the expression of human CYP1A2. The
3-[(3-cholamidopropyl)-dimethylamonio]-1-propanesulfonate (CHAPS)-solubilized E. coli
preparations of pig and human CYP1A2 were used to make a comparison of their catalytic
properties. In the EROD and MEROD assays, it was found that the Km’s of these two
enzymes are very similar suggesting that pig and human CYP1A2 have practically the same
affinity for these reactions. However, the Vmax’s of these enzymes for these oxidations
showed differences indicating that pig CYP1A2 catalyses the MEROD better than the
human counterpart. Thus, in agreement with correlation coefficient data, this activity may
be a useful marker for the CYP1A2 isoform in pig.
Inhibition experiments further suggested a certain difference of the biochemical properties
between pig and human CYP1A2 enzymes. Compared with the results obtained, ellipticine
was a better inhibitor of EROD activity catalysed by pig CYP1A2 rather than human
orthologue, whereas the reverse was found for -naphthoflavone.
We have also examined the relative tissue distribution of CYP1A2 in pig and found that
the enzyme was mainly expressed in the liver, although it was also detected, at least at the
mRNA level, in heart and nasal mucosa. This predominantly hepatic expression is in
agreement with what has been reported in humans and some other mammals (Lewis and
Lake 1996; Guengerich 1997).
The results obtained in the present study indicate that the biochemical properties of the
purified porcine CYP1A2 are considerably similar to those of the corresponding human
enzyme. From the analysis of cloned porcine CYP1A2 cDNA, it was observed that the
nucleotide and deduced amino acid sequences had 85% and 81% identities to those of
the human counterparts, respectively. A high degree of similarity was also found among the
SRSs of the porcine and human CYP1A2.
In conclusion, taken together these results suggest that hepatic CYP1A2 in pig and
human may have a similar function in the biotransformation of endobiotic and xenobiotic
compounds. The availability of an adequate amount of porcine CYP1A2, which has never
been expressed in a heterologous system, can now facilitate a systematic investigation of the
substrate specificity of drugs on development. The evaluation of toxicity and metabolism of
new drugs is based on experiments with animal systems and, therefore, the selection of
an appropriate animal model such as the pig is of great importance. This investigation
extends our knowledge of the CYP-dependent drug-metabolizing system in pig and
contributes to the idea that this animal is a useful human model in toxicological and
pharmacological studies.
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